Definition of Mogamulizumab. Meaning of Mogamulizumab. Synonyms of Mogamulizumab

- Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor type 4 (CCR4). It...
- a few others are a second-line drug for cutaneous T-cell lymphoma. Mogamulizumab has been approved in ****an and the United States. The FDA has approved...
- antagonist used as a treatment for pruritus in cutaneous T-cell lymphoma. Mogamulizumab is a CCR4 monoclonal antibody which has been shown to improve progression-free...
- potential use of a TBP-2 inducer as a novel therapeutic target. In 2021, mogamulizumab was approved for relapsed/refractor treatment of ATL in ****an. At a...
- approval in ****an in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform. Central nervous system medicines...
- often expressed on leukemic cells in cutaneous T-cell lymphoma (CTCL). Mogamulizumab is a humanised monoclonal antibody targeted at CCR4 and is an investigational...
- cyclic peptide histone deacetylase (HDAC) inhibitor (2018) Poteligeo (mogamulizumab-kpkc) Histone deacetylase (HDAC) inhibitors are shown to have antiproliferative...
- improvement in motor and bladder function was reported but not sustainable. Mogamulizumab, an anti-CCR4 IgG1 monoclonal antibody, is also being researched as...
- CCR4 Agonists: CCL3 (MIP-1α) CCL5 (RANTES) CCL17 CCL22 Antibodies: Mogamulizumab (against CCR4) CCR5 Agonists: CCL3 (MIP-1α) CCL4 (MIP-1β) CCL5 (RANTES)...
- CCR4 Agonists: CCL3 (MIP-1α) CCL5 (RANTES) CCL17 CCL22 Antibodies: Mogamulizumab (against CCR4) CCR5 Agonists: CCL3 (MIP-1α) CCL4 (MIP-1β) CCL5 (RANTES)...